108 Results for "

macular degeneration

" in MedChemExpress (MCE) Product Catalog:
Products (108)

108 Results for "macular degeneration" in MCE Product Catalog:

291
291 Publications Verification
Cat. No.: HY-B0146
CAS No.: 129497-78-5
Synonyms: CL 318952
Research Areas:  

Cancer

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-112467
CAS No.: 682745-40-0
Purity:  ≥99.0%
Synonyms: AV-951 hydrate; KRN951 hydrate
Target:  

VEGFR

Research Areas:  

Cancer

Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-129241
CAS No.: 330834-54-3
Purity:  99.33%
AGX51 is a pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist that disrupts ID-E protein interactions, thereby triggering ubiquitin-mediated proteasomal degradation of ID1, ID2, ID3 and ID4. AGX51 induces ROS production, G0/G1 cell cycle arrest, non-apoptotic cell death, and regulates EMT-related proteins. AGX51 reduces the proliferation, migration and myofibroblast differentiation of lung fibroblasts, alleviates pulmonary fibrosis, inhibits cancer cell viability and tumor growth, impairs neovascularization, and shows no obvious toxicity in mice. AGX51 can be used in research related to idiopathic pulmonary fibrosis, triple-negative breast cancer, breast cancer, pancreatic ductal adenocarcinoma, colorectal tumors, wet age-related macular degeneration and retinopathy of prematurity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N6947
CAS No.: 127-40-2
Synonyms: Xanthophyll
Lutein (Xanthophyll) is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health . Lutein exerts its biological activities, including anti-inflammation, anti-oxidase and anti-apoptosis, through effects on reactive oxygen species (ROS) . Lutein is able to arrive in the brain and shows antidepressant-like and neuroprotective effects. Lutein is orally active .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-128973
CAS No.: 24533-72-0
Purity:  ≥98.0%
Research Areas:  

Cancer

Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-110195
CAS No.: 1007647-73-5
Purity:  99.81%
Synonyms: A01
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P3252A
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9951A
CAS No.: 347396-82-1
Synonyms: RG-6321 (anti-VEGF)

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107543
CAS No.: 634207-53-7
Purity:  99.81%
Synonyms: 8-CPT-2'-O-Me-cAMP sodium
Target:  

Ras

Research Areas:  

Cardiovascular Disease

8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99905
CAS No.: 2375661-82-6
Synonyms: IBI302

Target:  

VEGFR

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3204
CAS No.: 934461-40-2
Synonyms: AL-78898A
Target:  

Complement System

Research Areas:  

Metabolic Disease

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12093
CAS No.: 1025716-81-7
Target:  

MMP

Research Areas:  

Inflammation/Immunology

MMP408 is a selective and orally effective inhibitor of MMP-12 with IC50 values for human, mouse and rat MMP-12 of 2 nM, 160 nM and 3 μM respectively. MMP408 exhibits IC50 value for human MMP-13 of 120 nM, and its activity against other MMPs is weak. MMP408 can alleviate inflammation, fibrosis and tissue remodeling by inhibiting MMP-12. MMP408 can be used in the research of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16959
CAS No.: 816432-15-2
Target:  

Inhibitory Antibodies

Research Areas:  

Others

CEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10186
CAS No.: 867331-82-6
Purity:  98.61%
Target:  

VEGFR FGFR PDGFR Src

Research Areas:  

Cancer

TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109020
CAS No.: 1229453-99-9
Purity:  99.84%
Synonyms: LHA510
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Acrizanib (LHA510) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16467
CAS No.: 320725-47-1
Synonyms: MSI-1256F
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15492
CAS No.: 319460-94-1
Purity:  99.71%
Synonyms: AG-013958
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
loading...
    loading...
Cat. No.: HY-147080
CAS No.: 1491144-00-3
Purity:  98.53%
Synonyms: ARC1905
Target:  

Complement System

Research Areas:  

Others

Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .
loading...
    loading...